Exquisite Timing, page-4

zecs, I think the most important part of that paragraph came after those words you have quoted:

This use has included in men whose cancer has failed to respond to the 177lutetium-PSMA alone, with Veyonda being used to overcome resistance to 177lutetium-PSMA, a potential major market opportunity

A cynic might say that mOS of 19.7 months in 56 patients is too small a sample to be reliable, but it is now clear that the combination of NOX66 plus Lu-PSMA is able to overcome resistance to Lu-PSMA alone. The evidence is incontrovertible: NOX66+Lu-PSMA is vastly superior to Lu-PSMA alone.